MX2020007656A - Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico. - Google Patents

Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico.

Info

Publication number
MX2020007656A
MX2020007656A MX2020007656A MX2020007656A MX2020007656A MX 2020007656 A MX2020007656 A MX 2020007656A MX 2020007656 A MX2020007656 A MX 2020007656A MX 2020007656 A MX2020007656 A MX 2020007656A MX 2020007656 A MX2020007656 A MX 2020007656A
Authority
MX
Mexico
Prior art keywords
crystalline form
palmitic acid
apomorphineâ
solid particle
acid cocrystal
Prior art date
Application number
MX2020007656A
Other languages
English (en)
Inventor
Nicolas Tesson
Carles Enrique Llaudet
Castaño Montserrat Trilla
Original Assignee
Leukos Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukos Biotech S L filed Critical Leukos Biotech S L
Publication of MX2020007656A publication Critical patent/MX2020007656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Abstract

Una composición farmacéutica que comprende apomorfina (APO) en una forma cristalina sólida, en donde la forma cristalina sólida es una forma cristalina de partículas sólidas de cocristal de APO·ácido palmítico.
MX2020007656A 2018-01-18 2019-01-15 Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico. MX2020007656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382023 2018-01-18
PCT/EP2019/050922 WO2019141673A1 (en) 2018-01-18 2019-01-15 Apomorphine·palmitic acid cocrystal solid particle crystalline form

Publications (1)

Publication Number Publication Date
MX2020007656A true MX2020007656A (es) 2020-09-18

Family

ID=61168020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007656A MX2020007656A (es) 2018-01-18 2019-01-15 Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico.

Country Status (11)

Country Link
US (1) US11382867B2 (es)
EP (1) EP3740190A1 (es)
JP (1) JP7303814B2 (es)
KR (1) KR20200110671A (es)
CN (1) CN111601587B (es)
AU (1) AU2019208396A1 (es)
BR (1) BR112020014598A2 (es)
CA (1) CA3088824A1 (es)
MX (1) MX2020007656A (es)
RU (1) RU2020126518A (es)
WO (1) WO2019141673A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248441A (zh) * 1998-09-23 2000-03-29 珠海经济特区生物化学制药厂 盐酸阿扑吗啡口含片及其用途
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
JP2004513899A (ja) 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
DK1610796T3 (da) 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
DK2854764T3 (en) * 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
EP2959904A1 (en) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Methods for treating, diagnosing and prognosing a haematological malignancy
WO2016103262A2 (en) 2014-12-23 2016-06-30 Neuroderm Ltd Crystal forms of apomorphine and uses thereof

Also Published As

Publication number Publication date
CA3088824A1 (en) 2019-07-25
EP3740190A1 (en) 2020-11-25
RU2020126518A (ru) 2022-02-21
US11382867B2 (en) 2022-07-12
WO2019141673A1 (en) 2019-07-25
CN111601587A (zh) 2020-08-28
US20200405648A1 (en) 2020-12-31
JP2021510687A (ja) 2021-04-30
BR112020014598A2 (pt) 2020-12-08
KR20200110671A (ko) 2020-09-24
JP7303814B2 (ja) 2023-07-05
CN111601587B (zh) 2024-03-05
AU2019208396A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
UY36275A (es) Compuestos aminopirimidinilo
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ723312A (en) 1,3-benzodioxole derivative
NZ742819A (en) Inhibitors of cxcr2
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
MX2016001424A (es) Composiciones edulcorantes.
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
WO2015168635A3 (en) Compositions and methods for modulating complement factor b expression
MX2015012743A (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
MX2020010657A (es) Derivados de oxadiazolina.
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
GEP20196982B (en) Pharmaceutical composition containing pyridylamino acetic acid compound
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2014153495A9 (en) Novel stat3 inhibitors
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2015014688A (es) Tiazoles y usos de los mismos.
PH12016500461A1 (en) Polyethylene glycol-containing composition
CA2904820C (en) Pyridinylpyrazoloquinoline compound
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
AU2016351424A8 (en) Pyranodipyridine compound
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
EA201990093A1 (ru) Двухкомпонентная композиция